A Real Shot at Remission, and a Real Chance It Doesn't Land
Her timing genuinely favors remission. What the same trial that gives her hope also shows, honestly, is that most participants who tried it still didn't get there — and that's the real disagreement underneath an otherwise hopeful conversation.
Monica S., a 44-year-old woman, runs a used bookstore she inherited from her aunt, work that keeps her on a step stool reaching for high shelves more often than she'd like to admit at her age. She was diagnosed with type 2 diabetes fourteen months ago, at a routine physical that caught an A1c of 7.6%, and has been managing since on metformin alone with reasonable but not excellent control. She read about the DiRECT trial — a structured, low-calorie diet program that achieved diabetes remission in a substantial share of participants — and asked directly whether that's a real option for her rather than staying on medication indefinitely.
Her timing works in her favor in a way the team takes seriously rather than treating as a generic hope: DiRECT's own data showed remission rates were highest specifically among patients whose diabetes had been diagnosed most recently, with the odds of achieving and sustaining normal glucose without medication declining the longer diabetes has been established. At fourteen months, she's well inside the window the trial found most favorable. What the same trial also showed, honestly, is that even among enrolled, highly supported participants, a meaningful share did not achieve durable remission at longer follow-up — a genuinely significant effect, not a guarantee, and one that leaves real disagreement about whether to bet on it alone or build in a pharmacologic backstop.
A real chance at remission, and a real chance it doesn't happen
I'd offer her a structured, DiRECT-style intensive dietary program as the first-line approach. Her diabetes duration — fourteen months — sits right in the window the trial found most predictive of actual remission. Starting medication first, before giving a genuine attempt a real chance, gives up an option that gets harder to achieve the longer her diabetes has been established.
I'd start effective pharmacotherapy now regardless. DiRECT's remission rates were real and meaningful, but a majority of even its carefully supported participants did not achieve durable remission at longer follow-up. Betting entirely on diet, for her specifically, risks continued hyperglycemia exposure if her outcome lands with that majority rather than the minority who achieved it.
I'm not arguing against the dietary program — I think she should absolutely try it. I'm arguing against treating "attempt remission" and "start effective medication" as mutually exclusive, when nothing about her situation actually requires that tradeoff.
I don't think this needs to be diet versus drugs at all. Start the structured dietary program and a GLP-1 receptor agonist together — these agents can themselves drive substantial weight loss and can carry patients to normal glucose without insulin — though the ADA/EASD consensus reserves the word remission for an A1c under 6.5% sustained at least three months after glucose-lowering drugs are stopped, so drug-maintained normal glucose is not itself remission. So this is not really adding a competing strategy, it's supporting the same one.
If she achieves genuine remission and the diet proves sustainable, the medication tapers off. If it doesn't fully get her there, she's not starting from scratch on pharmacotherapy months later — she's already on an effective regimen that was working alongside her real effort the whole time.
Monica enrolled in the structured dietary program with dietitian support, a GLP-1 receptor agonist started alongside it, and metformin continued in the interim. An explicit remission- assessment visit was scheduled at six months, with the medication taper plan documented in advance rather than decided reactively.
Not agreed: what specific criteria should count as "remission" for the purpose of tapering her medications — an A1c below a defined threshold sustained off metformin alone, or a stricter standard requiring normal glucose off all pharmacotherapy including the GLP-1 receptor agonist. The primary care physician favored the more inclusive definition; the endocrinologist wanted the stricter one before calling it a true remission. Left for the six-month visit to define more precisely.